VolitionRX(VNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VNRX VolitionRX

Pre-Mkt 12-24 04:16:44 EST

0.2547

-0.0128

-4.79%

High0.2660	Low0.2525	Vol1.46M
Open0.2630	D1 Closing0.2675	Amplitude5.05%
Mkt Cap31.28M	Tradable Cap22.70M	Total Shares122.80M
T/O378.02K	T/O Rate1.64%	Tradable Shares89.14M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VNRX","market":"US","secType":"STK","nameCN":"VolitionRX","latestPrice":0.2547,"timestamp":1766523600000,"preClose":0.2675,"halted":0,"volume":1460085,"delay":0,"floatShares":89140332,"shares":122801572,"eps":-0.22881,"marketStatus":"Pre-Mkt","change":-0.0128,"latestTime":"12-24 04:16:44 EST","open":0.263,"high":0.266,"low":0.2525,"amount":378021.7300332,"amplitude":0.050467,"askPrice":0.2919,"askSize":100,"bidPrice":0.25,"bidSize":6778,"shortable":3,"etf":0,"ttmEps":-0.22881,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766586600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1423198800000,"exchange":"AMEX","adjPreClose":0.2547,"postHourTrading":{"tag":"盘后","latestPrice":0.2525,"preClose":0.2547,"latestTime":"19:58 EST","volume":30501,"amount":7834.3168,"timestamp":1766537882515},"volumeRatio":0.37462144908888306,"impliedVol":0.1508,"impliedVolPercentile":0.2892},"requestUrl":"/m/hq/s/VNRX","defaultTab":"news","newsList":[{"id":"2592590580","title":"VolitionRX Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2592590580","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592590580?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:33","pubTimestamp":1766061180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VNRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2025 07:33 ET (12:33 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX"],"gpt_icon":0},{"id":"2592091801","title":"VolitionRX Signs Licencing Agreements With Werfen and Hologic","url":"https://stock-news.laohu8.com/highlight/detail?id=2592091801","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592091801?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:45","pubTimestamp":1765979120,"startTime":"0","endTime":"0","summary":"VolitionRx Limited announced the signing of two agreements in 2025 as part of its human licensing strategy. The first agreement is with Werfen for Antiphospholipid Syndrome , and the second is a Co-Marketing and Services Agreement with Hologic. Additionally, in March, VolitionRx signed an agreement with a leading pharmaceutical company to use its Nu.Q Discover biomarkers in a longitudinal Phase 1/2b clinical study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on December 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL9kJMD1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1951198990.SGD","LU1923623000.USD","LU2125909593.SGD","BK4082","BK4588","LU0314104364.USD","LU1951200564.SGD","BK4198","HOLX","LU1923622614.USD","VNRX","LU2433249047.HKD","LU2125909247.SGD","BK4585","LU0823416689.USD"],"gpt_icon":0},{"id":"2590540544","title":"VolitionRX Ltd - on Dec 5 Volition Veterinary Terminated CEO DR. Butera Effective January 31, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590540544","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590540544?lang=en_us&edition=fundamental","pubTime":"2025-12-12 06:01","pubTimestamp":1765490518,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH16K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2590544505","title":"Volition Veterinary Eliminates CEO Role Amid Cost Realignment","url":"https://stock-news.laohu8.com/highlight/detail?id=2590544505","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590544505?lang=en_us&edition=fundamental","pubTime":"2025-12-12 06:01","pubTimestamp":1765490464,"startTime":"0","endTime":"0","summary":"Volition Veterinary, a VolitionRX Subsidiary, to Eliminate CEO Position in Cost-Realignment Move. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL8rHVGW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2590511820","title":"VolitionRX Unveils Breakthrough Liquid Biopsy Method Achieving 100% Cancer Detection in Early Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2590511820","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590511820?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:01","pubTimestamp":1765461669,"startTime":"0","endTime":"0","summary":"VolitionRx Ltd. has announced the preprint availability of a new manuscript detailing a novel method, Capture-Seq, and new biomarkers for cancer detection. The study involved a training cohort of 70 individuals, including 49 patients with breast, prostate, lung, or colorectal cancer. Results showed that the analysis of ultrashort transcription factor-bound DNA in plasma detected all cancer patients  and produced no false positives , including those with early-stage disease. These initial findings have not yet been validated in larger independent studies. The company also reported achieving a 180-fold enrichment of target DNA fragments and indicated that the technology may expand its Nu.Q portfolio. The results have been made available in a preprint and have not yet been presented in a peer-reviewed forum.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL5D90Kg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2589356690","title":"VolitionRx Unveils Promising Nu.Q Cancer Blood Test Data for Lung Cancer Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2589356690","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589356690?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:00","pubTimestamp":1765202459,"startTime":"0","endTime":"0","summary":"VolitionRx Ltd., a multi-national epigenetics company, announced the presentation of two abstracts at the North America Conference on Lung Cancer  in Chicago. The studies highlighted the use of Volition's Nu.Q Cancer assays in the management of lung cancer patients. Results from these studies were presented at the conference. One study demonstrated that Nu.Q Cancer assays, particularly the measurement of circulating H3K27Me3-nucleosomes, can support clinicians in treatment selection and patient monitoring, potentially improving prognostic accuracy and informing personalized care strategies. Another study found that pre-operative measurement of H3K27Me3-nucleosomes through a blood test may help stratify risk in Non Small Cell Lung Cancer patients, particularly in identifying those who may benefit from closer follow-up or additional treatment. The research indicates that Nu.Q-H3K27Me3 levels correlate with cancer stage and could serve as an independent prognostic biomarker for overall su","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL1r5YFR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2589566853","title":"Volition Announces Two Abstracts Were Presented at the North America Conference on Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2589566853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589566853?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:00","pubTimestamp":1765202406,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA899SPZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2588470887","title":"VolitionRx Nu.Q NETs Assay Selected for French Sepsis Detection Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2588470887","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588470887?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:02","pubTimestamp":1764856921,"startTime":"0","endTime":"0","summary":"VolitionRx Limited has announced the inclusion of its Nu.Q NETs H3.1 assay in the DETECSEPS real-world evaluation study for early detection of sepsis in France. The DETECSEPS Consortium, supported by approximately 6.3 million in French government funding as part of the France 2030 plan, will utilize the Nu.Q H3.1 assay as the sole biomarker in the study. The assay is designed to be used alongside the NEWS2 diagnostic test and can be processed using the Immunodiagnostic Systems  i10 automated analyzer. Results from the study have not yet been presented and are expected in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire  on December","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL1TS8wN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","RVTY","VNRX","BK4121","BK4585","BK4588"],"gpt_icon":0},{"id":"2588029512","title":"VolitionRX Shares Fall After Maxim Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2588029512","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588029512?lang=en_us&edition=fundamental","pubTime":"2025-12-04 03:58","pubTimestamp":1764791898,"startTime":"0","endTime":"0","summary":"VolitionRX (VNRX) shares were down nearly 7% in recent Wednesday trading after Maxim downgraded the company's stock to hold from buy.Trading volume stood at about 782,000 shares against a daily average of around 1.2 million.Price: 0.28, Change: -0.02, Percent Change: -6.86","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VNRX"],"gpt_icon":0},{"id":"2588026499","title":"VolitionRX Cut to Hold From Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2588026499","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588026499?lang=en_us&edition=fundamental","pubTime":"2025-12-04 03:19","pubTimestamp":1764789540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VNRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2025 14:19 ET (19:19 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2588416210","title":"Maxim Downgrades VolitionRX to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588416210","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588416210?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:39","pubTimestamp":1764769183,"startTime":"0","endTime":"0","summary":"VolitionRX (VNRX) has an average rating of overweight and mean price target of $2.69, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VNRX"],"gpt_icon":0},{"id":"2588704967","title":"VolitionRX Ltd : Maxim Group Cuts to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588704967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588704967?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:11","pubTimestamp":1764767494,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2586646572","title":"VolitionRX Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2586646572","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586646572?lang=en_us&edition=fundamental","pubTime":"2025-11-27 02:06","pubTimestamp":1764180360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VNRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 26, 2025 13:06 ET (18:06 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX"],"gpt_icon":0},{"id":"2586476539","title":"VolitionRx Secures First Sale of Nu.Q Cancer Assays to Hospices Civils de Lyon","url":"https://stock-news.laohu8.com/highlight/detail?id=2586476539","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586476539?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:45","pubTimestamp":1764078313,"startTime":"0","endTime":"0","summary":"VolitionRx Limited has announced the first sale of its Nu.Q Cancer assays to the Hospices Civils de Lyon, one of Europe's leading cancer centers in Lyon, France. The order was placed to complete the internal certification process in preparation for introducing the test into routine clinical practice for cancer management within the hospital network. This sale marks a step toward the potential routine clinical use of Nu.Q Cancer assays for patient management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire  on November 25, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDLbGyx1L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2586476533","title":"VolitionRX Limited Announces the First Sale of the Nu.q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2586476533","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586476533?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:45","pubTimestamp":1764078300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nTUA60CWDS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2584673703","title":"VolitionRX Ltd. President and CEO Cameron John Reynolds Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584673703","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584673703?lang=en_us&edition=fundamental","pubTime":"2025-11-18 02:12","pubTimestamp":1763403168,"startTime":"0","endTime":"0","summary":"Cameron John Reynolds, President and CEO of VolitionRX Ltd., has reported the acquisition of common shares of VolitionRX Ltd. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL4GLKmc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"VolitionRX Ltd. President and CEO Cameron John Reynolds Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"gpt_icon":0},{"id":"2584362097","title":"VolitionRx price target lowered to $1.50 from $2.50 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2584362097","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584362097?lang=en_us&edition=fundamental","pubTime":"2025-11-18 00:25","pubTimestamp":1763396714,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on VolitionRx (VNRX) to $1.50 from $2.50 and keeps a Buy rating on the shares. VolitionRx posted Q3...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/volitionrx-price-target-lowered-to-1-50-from-2-50-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/volitionrx-price-target-lowered-to-1-50-from-2-50-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2584620369","title":"VolitionRX Ltd. : H.c. Wainwright Cuts Target Price to $1.5 From $2.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2584620369","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584620369?lang=en_us&edition=fundamental","pubTime":"2025-11-18 00:21","pubTimestamp":1763396500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nAZN4QTUN4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4198","VNRX"],"gpt_icon":0},{"id":"2584626369","title":"VolitionRX Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584626369","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584626369?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:19","pubTimestamp":1763385540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VNRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 08:19 ET (13:19 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX"],"gpt_icon":0},{"id":"2583578780","title":"VolitionRX Ltd. unveils corporate presentation highlighting epigenetic diagnostics and global licensing strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2583578780","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583578780?lang=en_us&edition=fundamental","pubTime":"2025-11-14 16:11","pubTimestamp":1763107862,"startTime":"0","endTime":"0","summary":"VolitionRX Ltd.  has released a corporate presentation highlighting its focus on commercial partnerships, IP licensing, and the development of low-cost diagnostic tests for cancer and sepsis. The company emphasizes its expertise in quantifying nucleosomes and measuring chromatin fragments, with products adaptable to various diagnostic workflows. VolitionRX outlines its strategy to monetize intellectual property through licensing agreements that provide upfront payments, milestone payments, and recurring revenue from royalties. The company targets broad geographic reach and large installed bases in its licensing and partnering efforts, with ongoing commercial validation through partnerships such as those with Antech and Fujifilm. VolitionRX is pursuing multiple licensing deals in the human health sector and continues to target unmet needs in both human and veterinary diagnostics. You can access the full presentation through the link below.Disclaimer: This news brief was created by Publi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL3F2lhl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNRX","BK4198"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.volition.com","stockEarnings":[{"period":"1week","weight":0.052},{"period":"1month","weight":-0.209},{"period":"3month","weight":-0.5793},{"period":"6month","weight":-0.7066},{"period":"1year","weight":-0.5846},{"period":"ytd","weight":-0.5755}],"compareEarnings":[{"period":"1week","weight":0.0134},{"period":"1month","weight":0.0439},{"period":"3month","weight":0.0406},{"period":"6month","weight":0.1244},{"period":"1year","weight":0.1568},{"period":"ytd","weight":0.1738}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company is based in Henderson, Nevada.","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.113519},{"month":2,"riseRate":0.3,"avgChangeRate":-0.068577},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.06613},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.026908},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.041011},{"month":6,"riseRate":0.454545,"avgChangeRate":0.012813},{"month":7,"riseRate":0.272727,"avgChangeRate":-0.017569},{"month":8,"riseRate":0.545455,"avgChangeRate":0.012627},{"month":9,"riseRate":0.363636,"avgChangeRate":0.038825},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.008979},{"month":11,"riseRate":0.363636,"avgChangeRate":0.018412},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.03784}],"exchange":"AMEX","name":"VolitionRX","nameEN":"VolitionRX"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VolitionRX(VNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest VolitionRX(VNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"VolitionRX,VNRX,VolitionRX股票,VolitionRX股票老虎,VolitionRX股票老虎国际,VolitionRX行情,VolitionRX股票行情,VolitionRX股价,VolitionRX股市,VolitionRX股票价格,VolitionRX股票交易,VolitionRX股票购买,VolitionRX股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VolitionRX(VNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest VolitionRX(VNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}